Prognostic role of asymmetric dimethylarginine following coronary angiography and percutaneous coronary intervention: current evidence, limitations, and future directions

Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and a candidate marker of impaired endothelial nitric oxide signaling. Despite procedural advances, coronary artery disease (CAD) remains associated with residual risk after invasive investigation and revascularization. Objective. To critically synthesize evidence linking circulating ADMA to coronary anatomy, plaque characteristics, cardiovascular outcomes, and restenosis in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI), with special attention to type 2 diabetes mellitus (T2DM). Evidence synthesis. In a meta-analysis of nine prospective CAG/PCI studies (6,374 participants), high versus low ADMA was associated with all-cause mortality (adjusted pooled RR 2.11, 95% CI 1.38–3.21), cardiovascular mortality (2.95, 1.14–7.68), major adverse cardiovascular events (2.10, 1.35–3.27), and restenosis (4.57, 2.52–8.30) [13]. However, other prospective cohorts yielded weaker or null associations for recurrent cardiovascular events [24], and findings vary by population, endpoint, kidney function, and analytical method [14–16,19]. A 2023 optical coherence tomography study associated higher ADMA with plaque vulnerability and subsequent events after PCI [12]. Conclusions. ADMA is a biologically credible research biomarker and frequently correlates with adverse prognosis, but independent association is not synonymous with improved prediction or actionable clinical benefit. Contemporary, assay-standardized, externally validated studies in defined PCI populations, particularly patients with T2DM, are needed.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-12
DOI
https://doi.org/10.5281/zenodo.24172278
Primary Topic
Nitric Oxide and Endothelin Effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prognostic role of asymmetric dimethylarginine following coronary angiography and percutaneous coronary intervention: current evidence, limitations, and future directions

G. Kalandarova, Z. Shamansurova
Zenodo (CERN European Organization for Nuclear Research)
Nitric Oxide and Endothelin Effects
article

Prognostic role of asymmetric dimethylarginine following coronary angiography and percutaneous coronary intervention: current evidence, limitations, and future directions

G. Kalandarova, Z. Shamansurova
article en

Abstract

Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and a candidate marker of impaired endothelial nitric oxide signaling. Despite procedural advances, coronary artery disease (CAD) remains associated with residual risk after invasive investigation and revascularization. Objective. To critically synthesize evidence linking circulating ADMA to coronary anatomy, plaque characteristics, cardiovascular outcomes, and restenosis in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI), with special attention to type 2 diabetes mellitus (T2DM). Evidence synthesis. In a meta-analysis of nine prospective CAG/PCI studies (6,374 participants), high versus low ADMA was associated with all-cause mortality (adjusted pooled RR 2.11, 95% CI 1.38–3.21), cardiovascular mortality (2.95, 1.14–7.68), major adverse cardiovascular events (2.10, 1.35–3.27), and restenosis (4.57, 2.52–8.30) [13]. However, other prospective cohorts yielded weaker or null associations for recurrent cardiovascular events [24], and findings vary by population, endpoint, kidney function, and analytical method [14–16,19]. A 2023 optical coherence tomography study associated higher ADMA with plaque vulnerability and subsequent events after PCI [12]. Conclusions. ADMA is a biologically credible research biomarker and frequently correlates with adverse prognosis, but independent association is not synonymous with improved prediction or actionable clinical benefit. Contemporary, assay-standardized, externally validated studies in defined PCI populations, particularly patients with T2DM, are needed.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Nitric Oxide and Endothelin Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon